 |
|
|
|
|
 |
Drugs That Prolong the Q-T Interval and/or Induce Torsades de Pointes
Raymond L. Woosley, MD, PhD
Information from the medical literature, the FDA-approved drug labeling and reports submitted to the FDA Adverse Events Reporting System database.
|
| |
Browse by clicking on the first letter of the drug's brand or generic name:
A · B · C · D · E · F · G · H · I · J · K · L · M
|
| |
| Generic Name |
|
Ephedrine |
More Info |
| Brand Name(s) |
|
Broncholate®,Rynatuss® |
| Drug Class |
|
Bronchodilator, decongestant |
|
|
|
|
| QT |
|
|
|
| TdP |
|
|
|
| Risk Group |
|
A drug to be avoided for use in patients with diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
|
| |
|
|
| |
|
|
|
| Generic Name |
|
Galantamine |
More Info |
| Brand Name(s) |
|
Reminyl® |
| Drug Class |
|
Cholinesterase inhibitor |
|
|
|
|
| QT |
|
|
|
| TdP |
|
|
|
| Risk Group |
|
A drug that, in some reports, has been weakly associated with Torsades de Pointes but that, when used in usual dosages, is unlikely to be a risk for Torsades de Pointes. |
|
| Comments |
|
|
| |
|
|
| |
|
|
|
| Generic Name |
|
Methylphenidate |
More Info |
| Brand Name(s) |
|
Concerta® ,Ritalin® |
| Drug Class |
|
CNS stimulant |
|
|
|
|
| QT |
|
|
|
| TdP |
|
|
|
| Risk Group |
|
A drug to be avoided for use in patients with diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
|
| |
|
|
| |
|
|
|
| Generic Name |
|
Ranolazine |
More Info |
| Brand Name(s) |
|
Ranexa® |
| Drug Class |
|
Anti-anginal |
|
|
|
|
| QT |
|
| QT prolongation is mentioned in the FDA-approved labeling as a known action of the drug. |
|
|
| TdP |
|
|
|
| Risk Group |
|
A drug that may prolong the QT interval but at this time lacks substantial evidence for causing Torsades de Pointes. This drug should be avoided for use in patients with diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
|
| |
|
|
| |
|
|
|
| Generic Name |
|
Risperidone |
More Info |
| Brand Name(s) |
|
Risperdal® |
| Drug Class |
|
Anti-psychotic |
|
|
|
|
| QT |
|
| QT prolongation is mentioned in the FDA-approved labeling as a known action of the drug. |
|
|
| TdP |
|
|
|
| Risk Group |
|
A drug that may prolong the QT interval but at this time lacks substantial evidence for causing Torsades de Pointes. This drug should be avoided for use in patients with diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
|
| |
|
|
| |
|
|
|
| Generic Name |
|
Ritodrine |
More Info |
| Brand Name(s) |
|
Yutopar® |
| Drug Class |
|
Uterine relaxant |
|
|
|
|
| QT |
|
|
|
| TdP |
|
|
|
| Risk Group |
|
A drug to be avoided for use in patients with diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
|
| |
|
|
| |
|
|
|
| Generic Name |
|
Roxithromycin* |
More Info |
| Brand Name(s) |
|
Rulide® |
| Drug Class |
|
Antibiotic |
|
|
|
|
| QT |
|
|
|
| TdP |
|
|
|
| Risk Group |
|
A drug that may prolong the QT interval but at this time lacks substantial evidence for causing Torsades de Pointes. This drug should be avoided for use in patients with diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
*not available in the United States |
|
| |
|
|
| |
|
|
|
|
| |
A note about Brand Names: Drugs are listed with up to 2 common brand names. There are many more brand names for some of the common drugs, such as pseudoephedrine and erythromycin. It is also important to look at the list of active drugs in medicines that contain a combination of drugs such as Zyrtec-D®, which contains pseudoephedrine. |
| |
|
| |
The University of Arizona Center for Education and Research on Therapeutics
Arizona Health Sciences Center
Tucson, Arizona 85724-5018
Funded in part by Agency for Healthcare Research and Quality grant 1 U18 HS10385-01
Disclaimer and Waiver
The information presented is intended solely for the purpose of providing general information about health related matters. It is not intended for any other purpose, including, but not limited to, medical or pharmaceutical advice and/or treatment, nor is it intended to substitute for the users' relationships with their own health care/pharmaceutical providers. To that extent, by continued use of this program, the user affirms the understanding of the purpose and releases the University of Arizona, State of Arizona and Arizona Board of Regents from any claims arising out of his/her use of the website.
|
|
